Rilpivirine: A next-generation non-nucleoside analogue for the treatment of HIV infection

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 7, 2012, Pages 1007-1014

  Fernández Montero, José Vicente ^a   Vispo, Eugenia ^a   Anta, Lourdes ^a   De Mendoza, Carmen ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Drug resistance; HIV; Rilpivirine

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CARBAMAZEPINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FAMOTIDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMYCIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

AGGRESSION; AGITATION; ANTIVIRAL RESISTANCE; ANXIETY; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BLURRED VISION; CLINICAL TRIAL (TOPIC); CLUSTER HEADACHE; CONFUSION; DEPRESSION; DIZZINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EAR DISEASE; EMOTIONAL DISORDER; FACIAL NERVE PARALYSIS; GENE MUTATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LETHARGY; MEMORY DISORDER; MONONEUROPATHY; NAUSEA; NEUROPATHY; NONHUMAN; PARESTHESIA; PHOTOPHOBIA; PSYCHOPATHY; RESTLESSNESS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS; VERTIGO; VIVID DREAM;

HIV INFECTIONS; HUMANS; MOLECULAR STRUCTURE; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84860159169     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.667802     Document Type: Article

References (27)

1. Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34 (Pubitemid 44306484)
2. Das K, Bauman J, Clark A, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 2008;105:1466-71 (Pubitemid 351346537)
3. Das K, Clark A, Lewi P, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-60 (Pubitemid 38580092)
4. Lansdon E, Brendza K, Hung M, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010;53:4295-9
5. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010;85(1):176-89
6. De Bethune M, Andries K, Azijn H, et al. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [abstract 556]. 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston, MA
7. Verloes R, Van't Klooster G, Baert L, et al. TMC278 long acting-a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers [abstract TUPE0042]. XVIIth International AIDS Conference; 3-8 August 2008; Mexico City, Mexico
8. Pozniak A, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010;24:55-65
9. Crauwels H, Williams P, Boven K, et al. TMC278 drug-drug interactions: an overview [abstract TPOI-4]. 4th Annual American Conference for the Treatment of HIV (ACTHIV); 7-9 April 2011; Denver, CO, USA
10. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase III randomized double-blind active-controlled trial. Lancet 2011;378:238-46
11. Cohen C, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase III, randomised, non-inferiority trial. Lancet 2011;378:229-37
12. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race analyses on week 48 efficacy and safety findings in treatment-naive, HIV-1-infected patients enrolled in ECHO and THRIVE [abstract 1124]. 48th Annual Meeting of the Infectious Diseases Society of America; 21-24 October 2010; Vancouver, Canada
13. Cohen C, Molina JM, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults [abstract TULBPE 032]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy
14. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011;16(3):339-48
15. Gallego L, Barreiro P, Lopez-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev 2011;13(3):171-9
16. Ford N, Lee J, Andrieux-Meyer I, et al. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl) 2011;3:35-44
17. Mills A, Antinori A, Clotet B, et al. Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naive, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks [abstract O-306]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA, USA
18. Wohl D, Doroana M, Orkin C, et al. Change in Vitamin D levels smaller and risk of development of severe Vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial [abstract 79-LB]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston, MA, USA
19. Edurant label information. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202022s000lbl.pdf [Last accessed 12 February 2012]
20. Edurant EMEA assessment report. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002264/ WC500118872.pdf [Last accessed 12 February 2012]
21. Xu H, Oliveira M, Quan Y, et al. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J Antimicrob Chemother 2010;65:2291-9
22. Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first-and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009;11:165-73
23. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27; K138N
24. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase III ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012;59(1):39-46
25. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011;85:11309-14
26. de Mendoza C, Anta L, Garcia F, et al. HIV-1 genotypic drug resistance interpretation rules-2009 Spanish guidelines. AIDS Rev 2009;11:39-51
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167. Available from: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf [Accessed 20 October 2011]